View ValuationARCpoint 将来の成長Future 基準チェック /06現在、 ARCpointの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare 収益成長19.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 11ARCpoint Inc. Announces CEO ChangesARCpoint Inc. announced that its Board of Directors had appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange, including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures. In connection with Mr. Kendall’s appointment, John Constantine has stepped down as Chief Executive Officer of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. Peter Kendall has more than twenty years of healthcare commercialization experience. His prior roles include President and Chief Commercialization Officer of AI/ML Innovations Inc., Chief Executive Officer of Yurek Pharmacy Group, and National Director at Medisys Health Group, subsequently acquired by TELUS Health. Mr. Kendall’s initial engagement is for a term of 90 days. During this period, Mr. Kendall will work with the Board and management to assess the Company's business model, MAPL technology platform, commercial relationships, assets and strategic direction, and to provide recommendations to the Board on the best commercial and financial path forward for the Company and its stakeholders.お知らせ • Jun 10Arcpoint Inc. Announces Step Down of John Constantine as PresidentARCpoint Inc. announced that John Constantine has stepped down as President of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. The Company’s Board members remain Zelong “Roger” He, David Keys, John Constantine and Adam Ho.お知らせ • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.お知らせ • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.お知らせ • Mar 09ARCpoint Inc. announced that it has received CAD 0.8 million in fundingOn March 7, 2025, ARCpoint Inc., closed the transaction. As a part of the transaction, the company paid CAD 36,057.60 as cash commission, issued 428,400 finder’s shares, 536,400 finder’s warrants. The transaction included participation from Felix Mirando and Adam Ho, purchased or acquired direction or control over a total of 764,199 units as part of the offering.お知らせ • Jan 31ARCpoint Inc. announced that it expects to receive CAD 0.8 million in fundingARCpoint Inc. announced a non-brokered private placement to issue 10,000,000 units at issue price of CAD 0.08 per unit for gross proceeds of CAD 800,000 on January 31, 2025. Each Unit will be comprised of one Class A Subordinate Voting Share of the Company and one warrant to purchase an additional Share at CAD 0.12 for 24 months from closing. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Subject to compliance with applicable securities laws and the approval of the TSX Venture Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.お知らせ • Dec 31An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million.An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million on December 30, 2024. A cash consideration of $0.48 million will be paid by the buyer.お知らせ • Aug 01ARCpoint Inc. announced that it has received CAD 1.004175 million in fundingOn July 31, 2024, ARCpoint Inc. closed the transaction. The company issued 13,389,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,004,175. In connection with the closing of the offering the company issued 670,900 finder’s shares, 1,013,900 finder’s warrants and paid a cash commission of CAD 60,834 to certain arm’s length finders. Each finder’s warrant entitles the holder thereof to purchase one share at a price of CAD 0.075 per finder’s warrant share until July 31, 2026. The offering remains subject to final acceptance from the TSX Venture Exchange. All securities issued in connection with the offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、ARCpoint は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:ARCP.F - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20251-2-1-1N/A9/30/20251-3-1-1N/A6/30/202533-2-2N/A3/31/202542-2-2N/A12/31/202461-3-3N/A9/30/20246-1-3-3N/A6/30/20247-7-3-3N/A3/31/20247-8-5-4N/A12/31/20237-9-5-4N/A9/30/20236-12-5-4N/A6/30/20236-12-6-5N/A3/31/20237-11-4-3N/A12/31/202211-8-20N/A9/30/202215-111N/A6/30/202219223N/A3/31/202219445N/A12/31/202119655N/A12/31/202013633N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ARCP.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ARCP.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ARCP.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ARCP.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ARCP.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ARCP.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/07 01:35終値2026/05/05 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ARCpoint Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 11ARCpoint Inc. Announces CEO ChangesARCpoint Inc. announced that its Board of Directors had appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange, including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures. In connection with Mr. Kendall’s appointment, John Constantine has stepped down as Chief Executive Officer of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. Peter Kendall has more than twenty years of healthcare commercialization experience. His prior roles include President and Chief Commercialization Officer of AI/ML Innovations Inc., Chief Executive Officer of Yurek Pharmacy Group, and National Director at Medisys Health Group, subsequently acquired by TELUS Health. Mr. Kendall’s initial engagement is for a term of 90 days. During this period, Mr. Kendall will work with the Board and management to assess the Company's business model, MAPL technology platform, commercial relationships, assets and strategic direction, and to provide recommendations to the Board on the best commercial and financial path forward for the Company and its stakeholders.
お知らせ • Jun 10Arcpoint Inc. Announces Step Down of John Constantine as PresidentARCpoint Inc. announced that John Constantine has stepped down as President of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. The Company’s Board members remain Zelong “Roger” He, David Keys, John Constantine and Adam Ho.
お知らせ • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.
お知らせ • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.
お知らせ • Mar 09ARCpoint Inc. announced that it has received CAD 0.8 million in fundingOn March 7, 2025, ARCpoint Inc., closed the transaction. As a part of the transaction, the company paid CAD 36,057.60 as cash commission, issued 428,400 finder’s shares, 536,400 finder’s warrants. The transaction included participation from Felix Mirando and Adam Ho, purchased or acquired direction or control over a total of 764,199 units as part of the offering.
お知らせ • Jan 31ARCpoint Inc. announced that it expects to receive CAD 0.8 million in fundingARCpoint Inc. announced a non-brokered private placement to issue 10,000,000 units at issue price of CAD 0.08 per unit for gross proceeds of CAD 800,000 on January 31, 2025. Each Unit will be comprised of one Class A Subordinate Voting Share of the Company and one warrant to purchase an additional Share at CAD 0.12 for 24 months from closing. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Subject to compliance with applicable securities laws and the approval of the TSX Venture Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.
お知らせ • Dec 31An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million.An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million on December 30, 2024. A cash consideration of $0.48 million will be paid by the buyer.
お知らせ • Aug 01ARCpoint Inc. announced that it has received CAD 1.004175 million in fundingOn July 31, 2024, ARCpoint Inc. closed the transaction. The company issued 13,389,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,004,175. In connection with the closing of the offering the company issued 670,900 finder’s shares, 1,013,900 finder’s warrants and paid a cash commission of CAD 60,834 to certain arm’s length finders. Each finder’s warrant entitles the holder thereof to purchase one share at a price of CAD 0.075 per finder’s warrant share until July 31, 2026. The offering remains subject to final acceptance from the TSX Venture Exchange. All securities issued in connection with the offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.